A combination trial evaluating BNT327/PM8002 with ADCs BNT323/DB-1303 (trastuzumab pamirtecan)
Latest Information Update: 21 Jan 2025
Price :
$35 *
At a glance
- Drugs BNT 323 (Primary) ; PM-8002 (Primary)
- Indications Breast cancer; Endometrial cancer; HER2 positive breast cancer; Liver cancer; Malignant-mesothelioma; Neuroectodermal tumours; Non-small cell lung cancer; Small cell lung cancer; Solid tumours; Triple negative breast cancer
- Focus Adverse reactions
- 21 Jan 2025 New trial record
- 14 Jan 2025 According to BioNTech media release, company plans to initiate this trial in 2025